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INTRODUCTION
Rosacea is a widely prevalent chronic cutaneous disorder with 
variable presentation and severity. It primarily affects blood vessels 
and pilosebaceous units of the central facial skin (cheeks, chin, 
nose, and central forehead), causing transient or persistent erythe-
ma, telangiectasias, papules, pustules, and phymatous changes 
(Fi gu re 1)(1).
Although considered a skin disease, rosacea may evolve the eyes 
in up to 58-72% of the patients, causing eyelid and ocular surface 
inflammation(1,2). About one third of the patients develop corneal 
involvement, which may be sight-threatening(1,3). 
Rosacea, albeit common, is often overlooked by general practi-
tioners and ophthalmologists(4). Mild rosacea patients may not seek 
medical help and may not be diagnosed in clinical practice. Ocular 
rosacea, in particular, is frequently underdiagnosed. Its symptoms 
and signs can be quite non-specific, and in up to 90% of patients, 
accompanying roseatic skin changes may be very subtle. More 
importantly, in 20% of the cases, ocular signs may even precede cha-
racteristic skin involvement(3). Patients often do not mention ocular 
symptoms in a dermatology clinic, unless directly asked about them. 
Conversely, skin manifestations are uncommonly examined during 
ophthalmology consults. As a result, a certain number of cases re-
main undetected(3).
Chronic, untreated rosacea may cause varying degrees of ocular 
morbidity, facial disfigurement, emotional distress, and social impair-
ment(5,6). The importance of early diagnosis and adequate treatment 
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cannot be overemphasized due to the negative impact this disorder may 
have on the quality of life of patients and the potential sight-threatening 
complications of this disease.
EpIDEmIOlOgy
Rosacea affects over 16 million Americans(7), and a Swedish survey 
revealed a prevalence as high as 10%(8). A recent large observational 
study on the epidemiology of rosacea in the United Kingdom revealed 
an incidence rate of 1.65/1,000 person-years as diagnosed by general 
prac titioners(9). Women are more commonly diagnosed with rosacea 
than men, and they tend to be diagnosed earlier. A possible explanation 
for this is that women may seek medical care more often and earlier than 
men. On the other hand, men are more prone to phymatous changes(9,10). 
Rhinophyma is most commonly seen in men over 40 years of age, in 
more advanced stages of the disease(11,12). 
Ocular rosacea affects both genders equally(9). The incidence of 
ocular rosacea varies among ophthalmologic and dermatologic stu-
dies, ranging from 6-72%, being more prevalent in ophthalmology 
clinics(2,3,13).
Rosacea may be found in early childhood as well as in the elderly, 
but it most commonly affects middle-aged adults(14). Spoendlin et 
al., found that 80% of rosacea patients in the UK were at or above 30 
years of age, with a peak in the incidence rate between the ages of 
40 and 59 years(9). Pediatric rosacea is thought to be rare, but may be 
underreported since the dermatologic features are often absent or 
difficult to identify(15-17). 
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ABSTRACT
Rosacea is a prevalent chronic cutaneous disorder with variable presentation and 
severity. Although considered a skin disease, rosacea may evolve the eyes in 58-72% 
of the patients, causing eyelid and ocular surface inflammation. About one third of 
the patients develop potentially sight-threatening corneal involvement. Untreated 
rosacea may cause varying degrees of ocular morbidity. The importance of early 
diagnosis and adequate treatment cannot be overemphasized. There is not yet a 
diagnostic test for rosacea. The diagnosis of ocular rosacea relies on observation 
of clinical features, which can be challenging in up to 90% of patients in whom 
accompanying roseatic skin changes may be subtle or inexistent. In this review, 
we describe the pathophysiologic mechanisms proposed in the literature, clinical 
features, diagnosis and management of ocular rosacea, as well as discuss the need 
for a diagnostic test for the disease.
Keywords: Rosacea/diagnosis; Eye manifestations; Eye diseases; Rosacea/drug therapy; 
Doxycycline; Visual acuity
RESUMO
A rosácea é uma condição cutânea crônica, que possui apresentações clínicas variáveis. 
Apesar de considerada uma doença dermatológica, os olhos podem ser acometidos em 
58-72% dos casos, causando inflamação palpebral e da superfície ocular. Aproximada-
mente um terço dos pacientes desenvolve acometimento corneano, podendo causar 
baixa visual significativa. Diagnóstico precoce e tratamento adequado são de extrema 
importância, devido à significativa morbidade ocular que a doença pode causar. Não 
há, até o momento, um teste diagnóstico para rosácea. O diagnóstico da rosácea ocular 
depende da observação das manifestações clínicas, o que pode ser bastante desafiador 
em até 90% dos pacientes, em que os achados cutâneos são discretos ou inexistentes. 
Nesta revisão, descrevemos os mecanismos fisiopatológicos propostos na literatura, 
manifestações clínicas, diagnóstico e tratamento da rosácea ocular, assim como abor-
damos a necessidade de um teste diagnóstico.
Descritores: Rosácea/diagnóstico; Manifestações oculares; Oftalmopatias; Rosácea/qui -
mioterapia; Doxiciclina; Acuidade visual
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Fair-skinned patients of European descent are more commonly 
affected by rosacea; however, any ethnicity can be afflicted with the 
disease. It has been suggested that skin pigmentation may obscure 
identification of the characteristic findings, contributing to under-
diagnosis in dark skinned patients(18).
ETIOlOgy AND pAThOphySIOlOgy
The precise etiology and pathophysiologic mechanisms of cuta-
neous and ocular rosacea remain unknown, although different theo-
ries have been proposed. Several studies confirm the inflammatory 
nature of the disease. An elevated concentration of interleukin-1a 
and b and a greater activity of gelatinase B (metalloproteinase -9) and 
colagenase-2 (MMP-8) have been found in tear fluids of patients with 
ocular rosacea(19-22). Doxycycline, used in the treatment of cutaneous 
and ocular rosacea, decreases both MMP-8 and MMP-9 activity(21,22). 
Tumor necrosis factor (TNF-alfa) was also elevated in rosacea(23). 
Significant overexpression of ICAM-1 (intercellular adhesion mole-
cule 1) and HLA-DR, inflammatory markers, was observed in con-
junctival epithelial cells of patients with rosacea(24). 
Recently, studies have shown that disease exacerbation is stimu-
lated by normal external environmental factors, leading to unique 
activation of pro-inflammatory systems as well as innate immune 
responses(23,25,26). Molecular studies propose that the enhanced 
sensitivity of patients with rosacea may be caused by abnormal 
recognition of common environmental stimuli. Factors that trigger 
the innate immune system lead to an increase in the expression of 
certain cytokines and anti-microbial molecules in the skin(25,27). Ca-
thelicidin, one of these antimicrobial peptides, has both vasoactive 
and pro-inflammatory actions and is implicated in the pathogenesis 
of this disorder. Based on the observation of a single molecule that 
presents both vasoactive and pro-inflammatory actions, researchers 
decided to study the behavior of such molecule in rosacea. As hypo-
thesized, these peptides were found in greater levels in the skin of 
individuals with rosacea than in normal facial skin(25,27,28). Moreover, 
the cathelicidin peptides found in rosacea patients were not only 
more abundant but were different from those found in normal indi-
viduals(25). These forms of cathelicidin peptides are known for its role 
in natural host defense against infections and in promoting leukocyte 
chemotaxis, angiogenesis, and extracellular matrix component 
expression(27). Supporting this theory, gene array studies found that 
mRNA expression levels of cathelicidin were found to be significantly 
increased in all subtypes of rosacea(29). Additionally, local proteases 
(serine protease KLK5) that control the production of cathelicidin in 
epidermis were also abnormally expressed in rosacea patients(25,27). 
To further test their hypothesis, researchers injected abnormal 
cathelicidin or protease that produce these peptides in the skin 
of mice and observed similar inflammatory features of the disease 
found in humans(27). Observation of higher amounts of receptors of 
the recognition system, Toll-like receptor 2 (TLR2), in the epidermis 
of patients with rosacea explained the overreaction of these patients 
to environmental stimuli, since enhanced action of TLR2 in kerati-
nocytes leads to an increase in serine protease KLK5 and cathelicidin 
production(23,25). Interestingly, tetracyclines, which improve signs and 
symptoms of rosacea, are known to inhibit expression and activity of 
several matrix metalloproteinases(21), as well as a class of proteases 
that activate cathelicidin, sustaining this theory(26,27). Furthermore, a 
recent study found elevated concentrations of 5 molecules involved 
in the innate immune response (interleukin-1b, interleukin-16, stem 
cell factor, monocyte chemotactic protein (MCP)-1, and monokine 
induced by g-interferon) in cutaneous biopsy specimens taken from 
ocular rosacea patients, supporting the concept that ocular rosacea 
is a disorder of innate immunity(30). 
Vascular dilation and incompetence contribute to the signs and 
symptoms of rosacea. The characteristic facial flushing, persistent 
erythema and telangiectasia may be caused by altered cutaneous 
neurovascular homeostasis. Studies have demonstrated increased 
blood flow in the face and larger and more numerous vessels in the 
face than in other areas of the body(31). Significantly dilated blood 
and lymphatic vessels were reported in all subtypes of rosacea(29). 
Studies further demonstrated an up-regulation of genes involved 
in vasoregulation and neurogenic inflammation and suggested that 
dysregulation of mediators and receptors implicated in neurovascu-
lar and neuroimmune communication may be crucial at early stages 
of rosacea(26,29,32). Improvement of erythema and flushing in rosacea 
by topical administration of a-adrenergic receptor agonists, oxyme-
tazoline and xylometazoline, helps support this theory(25,33,34). 
Cathelicidin causes endothelial changes(26). Angiogenesis indu-
ced by cathelicidin is mediated by an increase in vascular endothelial 
growth factor (VEGF) in epidermal keratinocytes, and could represent 
an explanation for these vascular events in rosacea(25). An increase in 
expression of VEGF and its receptors was demonstrated in the skin of 
patients with rosacea(35,36). 
Group IIA phospholipase A
2
, an antimicrobial protein capable of 
killing Gram-positive bacteria, is secreted into the tears by lacrimal 
glands and plays a role in innate host defense. A decreased concen-
tration of group IIA phospholipase A
2
 was found in tears of patients 
with ocular rosacea(37).
Microbial organisms such as Helicobacter pylori, Demodex folli-
culorum, Demodex brevis and Staphylococcus epidermidis have been 
appointed as other possible causative factors in exacerbation of the 
disease; however this remains a controversy(23,26,31,38-43). The prevalence 
of H. pylori infection was found higher in patients with rosacea when 
compared to the general population, and its eradication has been 
shown to influence the clinical outcome of this disease(31,39,44-46). Ho-
wever, other studies have not found such difference(41,47-49). Demodex, 
a microscopic mite found in hair follicles and sebaceous glands, is 
the most common ectoparasite in humans. Studies support its role 
in the activation of immune mechanisms in certain subtypes of 
rosacea, especially papulopustular rosacea(32). The Demodex count 
was shown significantly higher in patients with facial rosacea, and 
a study demonstrated a strong correlation between positive serum 
immunoreactivity and ocular Demodex infestation in facial rosacea 
and lid margin inflammation(41,50,51). Another proposed mechanism 
Figure 1. Cutaneous manifestations of rosacea with characteristic involvement of central 
facial skin (cheeks, nose, and central forehead).
Vieira ACC, et al.
365Arq Bras Oftalmol. 2012;75(5):363-9
is that Demodex mites may act as vectors for other microorganisms 
such as Bacillus olenorium, which may be responsible for initiation of 
inflammatory response in rosacea, through production of antigenic 
proteins and stimulation of Toll-like receptor 2 (TLR2)(23,25,38,42,50). 
DIAgNOSIS
The diagnosis of rosacea is clinical and relies on observation of 
skin manifestations. In cases in which these are only very subtle, the 
diagnosis can become very challenging and the disease may remain 
undiagnosed. In addition, manifestations of ocular rosacea are by no 
means specific to the disorder alone and other ophthalmologic di-
seases may present with similar findings, making the diagnosis even 
more difficult and the search for a diagnostic test quite important. 
Lack of diagnostic test
Unfortunately, there is not yet a diagnostic test available for either 
cutaneous or ocular rosacea(15). No serologic or histologic markers 
have been described to date. A diagnostic marker may enable earlier 
diagnosis and treatment, as well as contribute with an etiologic ex-
planation for this troublesome disorder. Our group has been working 
on the glycomic profile of tears and saliva of roseatic patients, as an 
initial step in the long pathway towards the search for a biomarker for 
the disease. We have previously shown a high abundance of O-linked 
oligosaccharides in the tears of patients with rosacea(52). More recen-
tly, we published our results on glycomic analysis of tears and saliva, 
and previous results were confirmed in both fluids with N-glycans 
dramatically decreased in roseatic tear and saliva samples(53). Fur-
thermore, we described highly novel glycans that may be potential 
biomarkers for rosacea(53).
cLassification and grading of rosacea
To aid in diagnosis, in 2002, an expert committee of the American 
National Rosacea Society published a standard classification system 
for rosacea(54). As well as serving as a diagnostic tool, this classification 
facilitates communication among dermatologists, researchers and 
other specialists(54,55). This important publication describes primary 
and secondary features of rosacea and defines 4 subtypes (erythe-
matotelangiectatic, papulopustular, phymatous and ocular rosacea) 
and 1 variant (granulomatous rosacea) of the disease(54). The primary 
and secondary features are listed in table 1. The presence of one or 
more of the primary signs with an axial facial distribution is indicative 
of rosacea. One or more of the secondary features may or may not 
be present.
Later, in 2004, the National Rosacea Society Expert Committee 
published a grading system to assess the severity of disease. Primary 
features were graded on a scale from 0 to 3 whether they were ab-
sent, mild, moderate, or severe, and most secondary features were 
graded as absent or present(56).
diagnosis of ocuLar rosacea
The diagnosis of ocular rosacea relies on observation of one or 
more of the following signs and symptoms: watery or bloodshot 
appearance (interpalpebral conjunctival hyperemia), foreign body 
sensation, burning or stinging, dryness, itching, light sensitivity, 
blurred vision, telangiectases of the conjunctiva and lid margin, lid 
and periocular erythema. Anterior blepharitis, meibomian gland dys-
function and irregularity of the eyelid margins may also be present(54). 
diagnosis of pediatric rosacea
The clinical features of pediatric rosacea are similar to those ob-
served in adults(16). However, in children, the dermatologic findings 
are often absent, making the diagnosis even more challenging and 
the identification of ocular manifestations especially important(15,17,57). 
A study revealed ocular symptoms to precede skin features in 55% 
of children(58). Ophthalmologists should maintain high suspicion in 
children with ocular surface disease, with or without cutaneous fea-
tures, to avoid misdiagnosis and complications(59). A positive family 
history of cutaneous rosacea and previous episodes of chalazia may 
be helpful in establishing the diagnosis(17). 
ClINICAl FINDINgS
rosacea
Symptoms may show periods of exacerbation and remission; 
however, the disease usually progresses over time. Some factors are 
known to worsen symptoms of rosacea and are referred to as trigger 
factors. Some examples of triggers are sun exposure, spicy foods, 
alcohol consumption, extreme temperatures, physical exercise, me-
nopause and emotional distress such as anger and embarrassment. 
These factors tend to be specific to each individual. A recent large 
epidemiologic study revealed that alcohol consumption is associa-
ted with only a small increase in risk of developing rosacea, whereas 
smoking may actually substantially reduce such risk(9).
Figure 2. Eyelid margin of a patient with ocular rosacea showing meibomian gland 
dysfunction and telangiectases.
Table 1. primary and secondary features of rosacea. Adapted from 
the Standard Classification of Rosacea, proposed by the National 
Rosacea Society Expert Committee, 2002(54)
primary features Description
Flushing (transient erythema) Frequent blushing or flushing
Nontransient erythema Persistent redness of the facial skin
Papules and pustules Red papules with or without pustules. Nodules 
may also occur
Telangiectasia Telangiectases are common but not necessary 
for a rosacea diagnosis
Secondary features Description
Burning or stinging sensations
Elevated plaques
Dry appearance Dry appearance of central facial skin
Edema Facial edema
Ocular manifestations
Peripheral location
Phymatous changes
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ocuLar rosacea
Patients with ocular rosacea may complain of foreign body sensa-
tion, dryness, itching, photophobia and tearing(10,60). Decreased visual 
acuity may result when corneal involvement is present. 
Ocular manifestations are usually bilateral and, as previously 
mentioned, can be non-specific(15). The severity of ocular rosacea 
symptoms is often not related to the severity of cutaneous manifes-
tations(15,31,51,60,61). One study found a significant relationship between 
ocular involvement and the severity of telangiectasia(62).
Eyelids and tear film
Blepharitis and meibomian gland dysfunction are common 
findings(3,15). Slit-lamp examination of the eyelid margins reveals 
telangiectases (Figure 2), dilated meibomian glands, excessive se-
borrheic secretion and collarettes around the eyelashes(15). Excessive 
meibomian secretion may lead to a soapy aspect of the inferior tear 
meniscus. Debris in the tear film may also be present. Recurrent 
hordeolum/chalazion and tear film insufficiency are commonly 
observed as a consequence of meibomian gland dysfunction(9,15). 
Dry eyes, with abnormal Schirmer test, were reported in 56-62.5% 
of patients with ocular rosacea(24,51,63). Diminished tear break-up time 
(TBUT) has also been reported in a large majority of patients with 
ocular rosacea(24,51,60). 
Facial edema is an uncommon manifestation(64). Periorbital ede-
ma has been reported in the literature and in one particular case, 
eyelid edema was severe enough to cause visual impairment(65,66).
Conjunctiva
Chronic conjunctivitis characterized by interpalpebral bulbar 
conjunctival hyperemia may be present(13,15), as well as a chronic pa-
pillary reaction(3). Cicatricial conjunctivitis involving the lower lid was 
described by Akpek et al. as one of the most common ocular surface 
findings in rosacea(67). Chronic cicatrizing conjunctivitis affecting 
mainly the upper eyelids, mimicking the classic findings in trachoma, 
has also been reported(68). Pinguecula and conjunctival fibrosis have 
been reported in up to 20% of patients with ocular rosacea(69,70). Starr 
and McDonald described a characteristic “arcade” of dilated vessels in 
the superficial limbal plexus, usually present in the inferior quadrants 
and not extending into the cornea(1). 
Symblepharon formation following surgical excision of a pyoge-
nic granuloma in a patient with ocular rosacea has been reported(71).
Cornea
Corneal manifestations may occur in up to 33% of patients with 
rosacea(1,3). The inferior cornea is usually affected(15). Corneal involve-
ment typically starts with superficial punctate keratitis on the lower 
third of the cornea. Peripheral neovascularization associated with 
subepithelial marginal triangular infiltrates along the advancing 
vascular border can also occur (Figure 3)(1). If left untreated, these 
infiltrates may progress centrally and lead to stromal ulceration and 
even perforation(15,72,73).
Recurrent corneal epithelial erosions have been reported in pa-
tients with ocular rosacea(67,74,75). Other uncommon corneal findings 
include pseudodendritic ulcer and pseudokeratoconus, presenting 
with inferior corneal thinning and high astigmatism(76-78). Secondary 
infectious keratitis has been reported(79,80).
Decreased visual acuity may result from epithelial ulceration, 
surface irregularities and corneal scarring.
Other ocular findings
Other ocular findings include iritis, episcleritis and scleritis(5,15). We 
have previously published a case of spontaneous scleral perforation 
in a patient with rosacea (Figure 4)(81).
Pediatric rosacea
The most common ocular signs in pediatric rosacea include 
meibomian gland dysfunction, telangiectasia, recurrent chalazia, 
conjunctival hyperemia, superficial punctate epitheliopathy invol-
ving the inferior cornea, as well as corneal infiltrates, pannus and 
neovascularization(16,58). Phlyctenular keratoconjunctivitis has also 
been associated with ocular rosacea in children(17). Corneal scarring 
and opacification are possible complications of more advanced 
disease(17). Donaldson et al., found that 90% of the children in their 
series had some degree of corneal involvement at the time of pre-
sentation(17).
DIFFERENTIAl DIAgNOSIS OF OCUlAR ROSACEA
The differential diagnosis of ocular rosacea may include staphylo-
coccal and seborrheic blepharokeratoconjunctivitis, and sebaceous 
gland carcinoma. Given that there is currently no diagnostic test 
for rosacea, distinguishing ocular rosacea from staphylococcal and 
seborrheic blepharoconjunctivitis in patients in which ocular signs 
precede skin findings may be difficult. Sebaceous gland carcinoma 
Figure 3. Corneal involvement in a patient with ocular rosacea: peripheral neovasculariza-
tion associated with subepithelial marginal infiltrates along the advancing vascular border. Figure 4. Scleral perforation in a patient with ocular rosacea.
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is often misdiagnosed as chalazion and early recognition is often 
challenging. For this reason, recurrent chalazia should be excised 
and sent to histopathology.
TREATmENT
Rosacea treatment should be initiated as early as possible in order 
to slow progression of inflammation and decrease development of 
irreversible fibrosis and ocular morbidity. The severity of the clinical 
findings and subtypes will help guide therapy. It is important to note 
that it is not uncommon for patients to present with an overlap of 
signs, showing features of more than one subtype of the disease(82). 
Clinicians should therefore identify the clinical features of the in-
dividual patient in order to guide the treatment, rather than try to 
fit the patient into one specific category. Treatment of eye-related 
symptoms alone may not be effective unless the underlying rosacea 
is diagnosed and adequately treated.
generaL measures
Initial management includes identification and avoidance of 
trig ger factors(10). These factors are usually specific to each indi-
vidual. Broad-spectrum sunscreen should be used daily for pho-
toprotection(11). Appropriate use of concealing makeup may help 
disguise upsetting facial features(83). Patients should be informed 
about the need and importance of regular eye exams(4).
medicaL treatment
Cutaneous rosacea
There are several treatment options available for rosacea but it is 
unclear which are the most effective. Early stages of rosacea may be 
controlled with topical regimens. Medications such as topical me-
tronidazole (0.75% and 1% formulations) and azelaic acid (15% gel 
or 20% cream) are approved for the treatment of mild to moderate 
papulopustular rosacea, showing similar results(15,61,82,84-88). Sodium 
sulfacetamide 10%/sulfur 5% preparations have also been used 
with satisfactory results; however, its association with metronida-
zole cream showed superior efficacy(89). Other topical treatments 
used “off-label” include clindamycin, erythromycin, pimecrolimus, 
tacrolimus and tretinoin(61,86,89). 
When topical treatment alone is not sufficient, systemic the-
rapy should be initiated. Oral tetracyclines (500 mg b.i.d.) and 
do xycycline (40-100 mg daily from 8-16 weeks) have been shown 
to safely improve the signs and symptoms of rosacea(84). In 2006, 
the FDA approved a daily formulation of 40 mg doxycycline mo -
nohydrate (Oracea®, Galderma) for the treatment of rosacea, al-
though other approved formulations of doxycycline are available. 
In unresponsive cases and when tetracyclines are contra-indicated 
or not tolerated, oral azithromycin (500 mg/day for 2 weeks) has 
been considered a good option(2,90,91). Oral isotretinoin (0.3 to 1.0 
mg/kg/day) is recommended in more severe intractable cases. The 
biggest disadvantage of this drug is the risk of teratogenicity and, 
therefore, all female patients in childbearing age should use proper 
contraception(92). 
Diffuse and persistent erythema in erythematotelangiectatic 
rosacea has been successfully treated with topical oxymetazoline 
0.05% and xylometazoline 0.05%, alpha-adrenergic receptor ago-
nists with strong vasoconstrictive properties(33,34). It is important 
to note that these medications are not yet FDA-approved for the 
treatment of rosacea, but have been published in case reports. 
Another a-agonist currently in study showing promising results for 
the treatment of facial erythema is brimonidine tartrate, a highly 
selective a2-adrenoreceptor agonist(82,93). Vascular laser therapy 
and intense pulsed light can be used for treatment of resistant 
skin telangiectasias and persistent erythema(15,61,93,94). 
Ocular rosacea
Management of mild ocular rosacea requires local measures such 
as warm compresses, lid hygiene with neutral baby shampoo and 
instillation of lubricating drops(2,83). Thicker lubricating agents, such 
as gels and ointments, may be prescribed for more symptomatic 
dry eyes to promote longer-lasting relief. Topical cyclosporine 0.05% 
helps increase tear production and quality(95). Antibiotic ointments 
prescribed daily, at bedtime, decreases eyelid flora and helps soften 
collarettes(61).
Moderate ocular rosacea may require systemic therapy(96). Oral 
tetracycline and doxycycline have been used to successfully treat 
ocular rosacea as an adjunct therapy to topical treatment(60,61,83,97). 
As in the management of skin rosacea, tetracyclines may be initially 
administered 500 mg b.i.d. for 2-3 weeks, and then tapered according 
to clinical response. Doxycycline possesses anti-angiogenic and anti-
-inflammatory properties as well as fewer side effects than first ge-
neration tetracyclines. Doxycycline may be prescribed in a regimen 
of 100 mg once or twice daily for 6 to 12 weeks. Many patients may 
present flare-ups once the medication is discontinued and may the-
refore require long-term maintenance therapy. However, long-term 
use of the drug at this dosage has side effects that may compromise 
regular treatment, such as gastrointestinal intolerance. As previously 
mentioned, the FDA approved a 40 mg doxycycline formulation 
(Oracea®, Galderma) for the treatment of rosacea. It contains 30 mg 
immediate-release and 10 mg delayed-release doxycycline that 
should be administered once daily(98). Significant improvement of 
ocular rosacea was obtained with regular use of controlled-release 
doxycycline 40 mg, with no side effects leading to discontinuation 
of therapy(85,99). Azithromycin improved eye symptoms and was con-
sidered a good alternative therapy for ocular rosacea, when other 
drugs are not tolerated(2). Long-term oral consumption of omega 
3 fatty acids has been shown to improve the quality of meibomian 
gland secretion(15).
In cases where persistent ocular surface inflammation, episcleritis, 
scleritis, iritis and sterile keratitis are present, topical corticosteroids 
or cyclosporine may prove beneficial(15,61,85,95,100). Topical cyclosporine 
0.05%, used twice daily, was also beneficial in reducing inflammation 
in posterior blepharitis(15). Long-term use of steroids should be avoi-
ded due to the potential side effects, such as glaucoma and cataracts, 
in which case the use of topical cyclosporine is preferable(15). 
In cases of secondary infectious keratitis, antimicrobial agents 
should be initiated promptly and topical steroids avoided or used 
with care, along with specific antimicrobial therapy(15,79).
Pediatric ocular rosacea
Initial treatment should include local measures such as warm 
compresses and eyelid hygiene with neutral baby shampoo. This 
routine may be difficult to maintain in children; however, the impor-
tance of these measures should be reinforced to the parents. Topical 
erythromycin ointment may also be used on the eyelid margins(58). 
Low-dose corticosteroid drops may be necessary to control ocular 
surface inflammation and treat keratitis, peripheral corneal vascula-
rization and scarring(17). 
As in adults, those patients with resistant disease should be pres-
cribed oral therapy. Systemic treatment of ocular childhood rosacea 
is very similar to that in adults, although one important difference 
is that tetracyclines are contra-indicated in children younger than 
7 years of age(58). Tetracycline and doxycycline, commonly used for 
therapy in adults, may result in depressed bone growth and dental 
staining in this age range(17). In these cases, erythromycin (20 mg/kg/
day) is preferable(16,17,101). Doxycycline (100 mg once or twice daily) is 
considered a good therapeutic option for older children, since it is 
usually better tolerated than tetracycline. Long-term treatment with 
systemic erythromycin and doxycycline proved beneficial in children 
with ocular rosacea(16). Azithromycin improved eye symptoms and 
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may also be considered in young children, where tetracyclines can-
not be prescribed(2). 
Surgical treatment
Punctal occlusion may be beneficial in the management of mo-
derate to severe dry eyes. Persistent chalazia may require surgical 
management and specimen should be sent to pathology.
Corneal thinning and perforations in ocular rosacea patients 
have been managed using simple corneal sutures, tissue adhesive, 
amniotic membrane transplantation, and conjunctival flaps(73,102-104). 
Lamellar or full-thickness keratoplasty are other options when surgi-
cal intervention becomes necessary, in cases of corneal perforation or 
opacification(15). Gracner and Gracner chose to perform a keratoplasty 
to successfully treat an extensive cornealscleral perforation(72). 
CONClUSION AND FUTURE pERSpECTIvES
Rosacea is a prevalent disorder that may be disfiguring and cause 
significant social impairment, as well as various degrees of ocular 
morbidity, if not diagnosed and managed appropriately. Ocular 
rosacea is often left undiagnosed and no specific diagnostic test is 
available to date. For this reason, diagnosis relies on a high level of 
suspicion and clinical observation of characteristic skin manifesta-
tions(54). This becomes very challenging in up to 20% of the patients, 
when ocular symptoms and signs precede cutaneous features(3). In 
these cases, a diagnostic test would be of great importance. Future 
studies may provide a biomarker and an etiologic explanation for this 
troublesome disorder.
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